SecBot SecBot
COURT-RULING ·Filed Jul 27, 2026

ABBV

AbbVie Inc.
BULLISH
Impact 6/10
Horizonmonths Processed3mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight ▲ Bullish

The denial of the stay removes near-term uncertainty around AbbVie's 340B program revenue. Monitor the Eighth Circuit appeal for a final ruling, but the district court's strong reasoning and the state's delay in seeking the stay suggest a low probability of reversal. This is a modest positive for ABBV's 340B-related earnings stream.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$263.20
T+0 close · Jul 28, 2026 · via day close
Latest settled
+8.21%
T+60 · $284.80
Vs SPY
+3.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $263.20entry
  2. T+1 · 4mo ago +0.04%α +1.58% · $263.30
  3. T+5 · 4mo ago −7.37%α −11.48% · $243.80
  4. T+20 · 3mo ago +0.98%α −2.40% · $265.79
  5. T+60 · 27d ago +8.21%α +3.86% · $284.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The District of North Dakota denied North Dakota's motion to stay a permanent injunction pending appeal, keeping AbbVie's win intact. The injunction blocks enforcement of a state law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program, with AbbVie estimating the law cost it $10M in 2025 and would cost another $35M in 2026 in discounted sales. The denial removes near-term uncertainty and preserves AbbVie's ability to operate under the federal program without state-imposed penalties, a material positive for its 340B revenue stream.

Court Ruling Details

Ruling Date
Jul 27, 2026
Court
United States District Court for the District of North Dakota
Court Level
District
Judge
Daniel M. Traynor
Case Type
regulatory
Ruling Type
other
Outcome
WIN: ruling favors this company
Appeal Status
Appeal filed or expected (per the opinion)
Appeal Timeline
1-2 years
Precedent Risk
LOW

Key Facts

  • Court denied North Dakota's motion to stay a permanent injunction pending appeal.
  • The permanent injunction blocks enforcement of a North Dakota law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program.
  • AbbVie estimated the law cost it $10 million in 2025 and will cost another $35 million in 2026 in discounted sales it would not make but for the law.
  • The court found North Dakota unlikely to succeed on the merits, citing the law's criminal penalties and direct price regulation as key differences from other state laws.
  • The ruling preserves the status quo and prevents North Dakota from re-imposing the law while the appeal proceeds.

Financial Impact

AbbVie estimated the law cost $10M in 2025 and will cost another $35M in 2026 in discounted sales it would not make but for the law. The denial of the stay preserves the injunction, avoiding these costs.

revenueoperating costs

Risk Factors

  • The Eighth Circuit could still reverse the permanent injunction on appeal, potentially re-exposing AbbVie to the law's costs.
  • Other states may enact similar laws, creating ongoing legal and regulatory risk for the 340B program.

Market Snapshot

Price
$263.34
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-2e6ca3056b-ABBV

Track record

22 reports on ABBV

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
  2. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
  3. Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  4. Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  5. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
  6. Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
  8. Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
  9. Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
  10. Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Jul 29, 2026